Back to results
US 2026/0306537 A1Published application
Intranasal delivery of cd34+ cells for the treatment of stroke
AssigneeCellprothera
InventorsIbon GARITAONANDIA, Christine VIGNON, Matthieu DE KALBERMATTEN
Life of this patent
Estimating the term…
Abstract
The disclosure relates to methods of treatment comprising intranasal delivery of CD34+ cells and CD34+ cells for use in such methods.
Claims17
A method of treating stroke comprising intranasally administering a population of CD34+ to a subject.
(canceled)
A method of treating stroke comprising administering a population of CD34+ cells to a subject:
- (a) wherein the CD34+ cells are administered to the subject intranasally, wherein the CD34+ cells secrete paracrine factors in an area affected by stroke thereby treating stroke;
- and/or
- (b) wherein the CD34+ cells are administered to the subject intranasally, wherein the CD34+ cells promote angiogenesis in an area affected by stroke, thereby treating stroke;
- and/or
- (c) wherein the CD34+ cells are administered to the subject intranasally, and wherein the CD34+ cells promote neurogenesis;
- and/or
- (d) wherein the CD34+ cells are administered to the subject intranasally, and wherein the CD34+ cells promote reduction in infarct size, and/or reduce cell loss in the infarct area and/or peri-infarct area and/or inflammation in the infarct area and/or peri-infarct area, thereby treating stroke;
- and/or
- (e) wherein the CD34+ cells are administered to the subject intranasally, and wherein the CD34+ cells promote motor and/or neurological recovery, thereby treating stroke.
6 more elements
A method of stimulating angiogenesis or neurogenesis comprising administering a population of CD34+ cells to a subject.
Dependencies are inferred from the claim text.